Compoundeer Logo
COMPOUNDEER
Uncovering Potential
RankingCompaniesDCF
BMRN Logo

Biomarin Pharmaceutical Inc

BMRN

Pharmaceutical Preparations

Mkt Cap

$16.6B

PE

112.89

Debt

$1.593B

Cash

$785.4M

EV

$17.4B

FCF

$35.1M

Market Cap

$16.6B

P/E Ratio

112.89

Debt

$1.593B

Cash

$785.4M

EV

$17.4B

FCF

$35.1M
Charts data: {"Earnings":[{"time":"2014-12-30","value":-133969000},{"time":"2015-12-30","value":-171799000},{"time":"2016-12-30","value":-630210000},{"time":"2017-12-30","value":-117042000},{"time":"2018-12-30","value":-77211000},{"time":"2019-12-30","value":-23848000},{"time":"2020-12-30","value":859100000},{"time":"2021-12-30","value":-64080000},{"time":"2022-12-30","value":141561000}],"Sales":[{"time":"2014-12-30","value":751040000},{"time":"2015-12-30","value":889895000},{"time":"2016-12-30","value":1116854000},{"time":"2017-12-30","value":1313646000},{"time":"2018-12-30","value":1491212000},{"time":"2019-12-30","value":1704048000},{"time":"2020-12-30","value":1860455000},{"time":"2021-12-30","value":1846275000},{"time":"2022-12-30","value":2096039000}],"Net Margins":[{"time":"2014-12-30","value":-0.1783779825308905},{"time":"2015-12-30","value":-0.19305536046387495},{"time":"2016-12-30","value":-0.5642725011505533},{"time":"2017-12-30","value":-0.08909706267898658},{"time":"2018-12-30","value":-0.051777346212342715},{"time":"2019-12-30","value":-0.013994910941475827},{"time":"2020-12-30","value":0.46176876086763724},{"time":"2021-12-30","value":-0.034707722305723686},{"time":"2022-12-30","value":0.06753738837874677}],"Assets":[{"time":"2014-12-30","value":2490453000},{"time":"2015-12-30","value":3729368000},{"time":"2016-12-30","value":4023690000},{"time":"2017-12-30","value":4633125000},{"time":"2018-12-30","value":4427128000},{"time":"2019-12-30","value":4690039000},{"time":"2020-12-30","value":5848020000},{"time":"2021-12-30","value":6003325000},{"time":"2022-12-30","value":6375074000}],"Stockholders Equity":[{"time":"2014-12-30","value":1527894000},{"time":"2015-12-30","value":2400847000},{"time":"2016-12-30","value":2766275000},{"time":"2017-12-30","value":2808663000},{"time":"2018-12-30","value":2967940000},{"time":"2019-12-30","value":3122381000},{"time":"2020-12-30","value":4106002000},{"time":"2021-12-30","value":4270740000},{"time":"2022-12-30","value":4603156000}],"ROE":[{"time":"2014-12-30","value":-0.08768212978125446},{"time":"2015-12-30","value":-0.07155766277484571},{"time":"2016-12-30","value":-0.22781899847267534},{"time":"2017-12-30","value":-0.041671784760222215},{"time":"2018-12-30","value":-0.026015013780602034},{"time":"2019-12-30","value":-0.007637761054784794},{"time":"2020-12-30","value":0.20923029263015458},{"time":"2021-12-30","value":-0.015004425462566206},{"time":"2022-12-30","value":0.03075303118121567}],"ROA":[{"time":"2014-12-30","value":-0.03542568360053372},{"time":"2015-12-30","value":-0.02968384991773405},{"time":"2016-12-30","value":-0.1967226600458783},{"time":"2017-12-30","value":0.0014745986779981114},{"time":"2018-12-30","value":-0.022371388403497706},{"time":"2019-12-30","value":-0.015213306328582768},{"time":"2020-12-30","value":-0.0022251975882435424},{"time":"2021-12-30","value":-0.012551377778147943},{"time":"2022-12-30","value":0.02346262961026021}]}

BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease. The company's commercial products also comprise Palynziq, a PEGylated recombinant phenylalanine ammonia lyase enzyme, which is delivered through subcutaneous injection to reduce blood Phe concentrations; Brineura, a recombinant human tripeptidyl peptidase 1 for the treatment of patients with ceroid lipofuscinosis type 2, a form of Batten disease; Voxzogo, a once daily injection analog of c-type natriuretic peptide for the treatment of achondroplasia; and Aldurazyme, a purified protein designed to be identical to a naturally occurring form of the human enzyme alpha-L-iduronidase. In addition, it develops Roctavian, an adeno associated virus vector, for the treatment of patients with severe hemophilia A; BMN 331, an AAV5 mediated gene therapy, which is in Phase 1/2 clinical trial for people living with Hereditary Angioedema (HAE); and BMN 255 that is in Phase 1/2 clinical trial for treating primary hyperoxaluria. The company serves specialty pharmacies, hospitals, and non-U.S. government agencies, as well as distributors and pharmaceutical wholesalers in the United States, Europe, Latin America, and internationally. BioMarin Pharmaceutical Inc. has license and collaboration agreements with Sarepta Therapeutics, Ares Trading S.A., Catalyst Pharmaceutical Partners, Inc., and Asubio Pharma Co., Ltd. The company was incorporated in 1996 and is headquartered in San Rafael, California.

Sector

  • ABBV Logo

    ABBV

  • ABCL Logo

    ABCL

  • ABT Logo

    ABT

  • ABUS Logo

    ABUS

  • AGIO Logo

    AGIO

  • AKBA Logo

    AKBA

  • AKRO Logo

    AKRO

  • ALKS Logo

    ALKS

  • ALNY Logo

    ALNY

  • ALPN Logo

    ALPN

  • AMLX Logo

    AMLX

  • AMPH Logo

    AMPH

  • AMRN Logo

    AMRN

  • AMRX Logo

    AMRX

  • ANAB Logo

    ANAB

  • ANIP Logo

    ANIP

  • APLS Logo

    APLS

  • ARDX Logo

    ARDX

  • ARQT Logo

    ARQT

  • ARVN Logo

    ARVN

  • ARWR Logo

    ARWR

  • AUPH Logo

    AUPH

  • AVDL Logo

    AVDL

  • AVIR Logo

    AVIR

  • AVTE Logo

    AVTE

  • AXSM Logo

    AXSM

  • BBIO Logo

    BBIO

  • BCYC Logo

    BCYC

  • BGNE Logo

    BGNE

  • BHVN Logo

    BHVN

  • BMEA Logo

    BMEA

  • BMY Logo

    BMY

  • BPMC Logo

    BPMC

  • CBAY Logo

    CBAY

  • CDMO Logo

    CDMO

  • CERE Logo

    CERE

  • CMPS Logo

    CMPS

  • CNTA Logo

    CNTA

  • COGT Logo

    COGT

  • COLL Logo

    COLL

  • CORT Logo

    CORT

  • CPRX Logo

    CPRX

  • CRNX Logo

    CRNX

  • CTLT Logo

    CTLT

  • CYRX Logo

    CYRX

  • CYTK Logo

    CYTK

  • DAWN Logo

    DAWN

  • DCPH Logo

    DCPH

  • DVAX Logo

    DVAX

  • DYN Logo

    DYN

  • ELAN Logo

    ELAN

  • EOLS Logo

    EOLS

  • ETNB Logo

    ETNB

  • EWTX Logo

    EWTX

  • FOLD Logo

    FOLD

  • FULC Logo

    FULC

  • GERN Logo

    GERN

  • HRMY Logo

    HRMY

  • HROW Logo

    HROW

  • IDYA Logo

    IDYA

  • IGMS Logo

    IGMS

  • IMGN Logo

    IMGN

  • INSM Logo

    INSM

  • INVA Logo

    INVA

  • IONS Logo

    IONS

  • IRON Logo

    IRON

  • IRWD Logo

    IRWD

  • ITCI Logo

    ITCI

  • JANX Logo

    JANX

  • JAZZ Logo

    JAZZ

  • JNJ Logo

    JNJ

  • KALV Logo

    KALV

  • KNSA Logo

    KNSA

  • KROS Logo

    KROS

  • KRTX Logo

    KRTX

  • KURA Logo

    KURA

  • LFCR Logo

    LFCR

  • LGND Logo

    LGND

  • LLY Logo

    LLY

  • LQDA Logo

    LQDA

  • LXRX Logo

    LXRX

  • LYEL Logo

    LYEL

  • MDGL Logo

    MDGL

  • MGNX Logo

    MGNX

  • MIRM Logo

    MIRM

  • MLTX Logo

    MLTX

  • MNKD Logo

    MNKD

  • MORF Logo

    MORF

  • MRK Logo

    MRK

  • MRNS Logo

    MRNS

  • MRTX Logo

    MRTX

  • MRUS Logo

    MRUS

  • MRVI Logo

    MRVI

  • NATR Logo

    NATR

  • NRIX Logo

    NRIX

  • OCUL Logo

    OCUL

  • OGN Logo

    OGN

  • OLMA Logo

    OLMA

  • OPK Logo

    OPK

  • ORGO Logo

    ORGO

  • ORIC Logo

    ORIC

  • PAHC Logo

    PAHC

  • PBAJ Logo

    PBAJ

  • PBH Logo

    PBH

  • PCRX Logo

    PCRX

  • PFE Logo

    PFE

  • PGEN Logo

    PGEN

  • PHAT Logo

    PHAT

  • PLRX Logo

    PLRX

  • PNT Logo

    PNT

  • PRGO Logo

    PRGO

  • PRTA Logo

    PRTA

  • PTCT Logo

    PTCT

  • PTGX Logo

    PTGX

Growth

%

%

Discount

%

%

Multiple

g\r+10%+11%+12%+13%+14%
0%109887
+1%1110988
+2%13111098
+3%141311109
+4%1714121110
Years012345678910TV
FCF$35.1M$26.11M$19.42M$14.45M$10.74M$7.992M$5.945M$4.422M$3.289M$2.447M$1.82M$18.2M
DCF$22.7M$14.68M$9.498M$6.143M$3.974M$2.57M$1.662M$1.075M$695.5K$449.8K$4.498M
Value$67.95M

In the chart Earnings are multiplied by this value.

Earnings Growth -35%
Earnings Stability -64%


Competitiveness and MOAT

High margins render the company resilient under dire circumstances, hence able to drive competitors out or acquire them. ROE and ROA measure the average flow generated by each invested dollar. Their marginal value is a forecast of future growth, and it is considered by Buffett and Munger the most important single indicator.

Years12-201412-201512-201612-201712-201812-201912-202012-202112-2022TTM
Net Margin-18%-19%-56%-8.9%-5.2%-1.4%46%-3.5%6.8%6.4%
ROA-3.5%-3%-20%0.15%-2.2%-1.5%-0.22%-1.3%2.3%2.1%
ROE-8.8%-7.2%-23%-4.2%-2.6%-0.76%21%-1.5%3.1%3%

What is the average Net Margin?

The average Net Margin over the past 5 years is +5.66%.

What is the trend of Net Margin?

The trend of Net Margin over the past 5 years is +3.74%.

What is the average Return on Assets (ROA)?

The average ROA over the past 5 years is -0.46%.

What is the trend of Return on Assets (ROA)?

The trend of ROA over the past 5 years is +0.44%.

What is the average Return on Equity (ROE)?

The average ROE over the past 5 years is +2.49%.

What is the trend of Return on Equity (ROE)?

The trend of ROE over the past 5 years is +1.75%.


Safety & Stabiliy

Being debt the number one cause of investment losses and company death, the ratio Debt/FCF is of utmost importance to guarantee safety. On the other hand the Graham’s stability measures the drawdown of earnings, hence indicating the reliability of the flow generated by the company.

Years12-201412-201512-201612-201712-201812-201912-202012-202112-2022TTM
Debt FCF--1.47-1.82-5.65-6.99-12.73-38.005.2620.0245.40
Debt Equity0.430.280.250.420.290.390.270.260.240.33
MIN
Graham Stability--------25%55%-25%

What is the Debt/FCF?

The Debt/FCF trailing twelve month is 45.40.

What is the trend of Debt/FCF?

The trend of Debt/FCF over the past 5 years is 4.00.

What is the Graham’s Stability?

Graham’s Stability measure stands at -0.25.


Growth

Growth can be dangerous when forecasting, simply projecting the current growth is in general wrong. A company passes through multiple phases, from being young and unprofitable, to the first periods of profitability and high growth, until it arrives at a period of regime with limited growth. Identifying in which phase the company is in may help forecasting.

Years12-201512-201712-201912-2021Trend
Revenue13%9.8%7.1%14%-2.3%
Net Income-----
Stockholders Equity9.7%10%14%7.8%-3.7%
FCF----74%-

What is the 5 year Revenue CAGR?

The Revenue CAGR over the past 5 years is +9.8%.

What is the trend of Revenue growth?

The trend of Revenue growth rate over the past 5 years is -2.27%.

What is the 5 year Earnings CAGR?

The Earnings CAGR over the past 5 years is -.

What is the trend of Earnings growth?

The trend of Earnings growth rate over the past 5 years is -.

What is the 5 year Equity CAGR?

The Equity CAGR over the past 5 years is +10.39%.

What is the trend of Equity growth?

The trend of Equity growth rate over the past 5 years is -3.71%.

What is the 5 year FCF CAGR?

The FCF CAGR over the past 5 years is -.

What is the trend of FCF growth?

The trend of FCF growth rate over the past 5 years is -.